tiprankstipranks
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
US Market
RYTM
Rhythm Pharmaceuticals
RESEARCH TOOLSreports
Want to see RYTM full AI Analyst Report?

Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

617 Followers
See the Price Targets and Ratings of:

RYTM Analyst Ratings

Strong Buy
15Ratings
Strong Buy
15 Buy
0 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Rhythm
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RYTM Stock 12 Month Forecast

Average Price Target

$142.47
▲(39.54% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is $142.47 with a high forecast of $160.00 and a low forecast of $105.00. The average price target represents a 39.54% change from the last price of $102.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"80":"$80","161":"$161","100.25":"$100.3","120.5":"$120.5","140.75":"$140.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$160.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":142.46666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$142.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[80,100.25,120.5,140.75,161],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.25,103.92307692307692,108.59615384615384,113.26923076923077,117.9423076923077,122.61538461538461,127.28846153846155,131.96153846153845,136.6346153846154,141.30769230769232,145.98076923076923,150.65384615384616,155.3269230769231,{"y":160,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.25,102.57435897435897,105.89871794871794,109.22307692307692,112.5474358974359,115.87179487179488,119.19615384615385,122.52051282051282,125.84487179487179,129.16923076923078,132.49358974358975,135.81794871794872,139.1423076923077,{"y":142.46666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.25,99.6923076923077,100.13461538461539,100.57692307692308,101.01923076923077,101.46153846153847,101.90384615384616,102.34615384615384,102.78846153846153,103.23076923076923,103.67307692307692,104.11538461538461,104.5576923076923,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":88.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.94,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.81,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.87,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.41,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.25,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$160.00Average Price Target$142.47Lowest Price Target$105.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on RYTM
Priyanka Grover
J.P. Morgan
J.P. Morgan
$146
Buy
43.00%
Upside
Reiterated
08/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Viatris (NASDAQ: VTRS)
Citizens JMP Analyst forecast on RYTM
Jonathan Wolleben
Citizens JMP
Citizens JMP
$155→$160
Buy
56.71%
Upside
Reiterated
08/05/26
Rhythm Pharmaceuticals price target raised to $160 from $155 at CitizensRhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
Canaccord Genuity Analyst forecast on RYTM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$151→$154
Buy
50.83%
Upside
Reiterated
08/05/26
Rhythm Pharmaceuticals price target raised to $154 from $151 at CanaccordRhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
Citi Analyst forecast on RYTM
Samantha Semenkow
Citi
Citi
$142→$143
Buy
40.06%
Upside
Reiterated
08/05/26
Citi Remains a Buy on Rhythm Pharmaceuticals (RYTM)
Morgan Stanley Analyst forecast on RYTM
Michael Ulz
Morgan Stanley
Morgan Stanley
$136→$150
Buy
46.91%
Upside
Assigned
08/05/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Morgan Stanley
Guggenheim Analyst forecast on RYTM
Seamus Fernandez
Guggenheim
Guggenheim
$143
Buy
40.06%
Upside
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on RYTM
Joseph Stringer
Needham
Needham
$130
Buy
27.33%
Upside
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on RYTM
Phil Nadeau
TD Cowen
TD Cowen
$130
Buy
27.33%
Upside
Assigned
08/04/26
Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Addus Homecare (NASDAQ: ADUS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Bank of America Securities Analyst forecast on RYTM
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$149
Buy
45.94%
Upside
Reiterated
08/04/26
Imcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated
RBC Capital Analyst forecast on RYTM
Lisa Walter
RBC Capital
RBC Capital
$141→$155
Buy
51.81%
Upside
Reiterated
08/04/26
Analysts' Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)
Wells Fargo Analyst forecast on RYTM
Derek Archila
Wells Fargo
Wells Fargo
$155
Buy
51.81%
Upside
Assigned
07/16/26
Wells Fargo Releases a Buy Rating on Rhythm Pharmaceuticals (RYTM)
H.C. Wainwright Analyst forecast on RYTM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$105
Buy
2.84%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals: Buy Rating Reiterated on Promising PWS Data and Large Market Opportunity; $105 Price Target Unchanged
Stifel Nicolaus Analyst forecast on RYTM
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$133
Buy
30.26%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Belite Bio, Inc. ADR (NASDAQ: BLTE)
Jefferies Analyst forecast on RYTM
Dennis Ding
Jefferies
Jefferies
$125
Buy
22.43%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies
Goldman Sachs Analyst forecast on RYTM
Corinne Johnson
Goldman Sachs
Goldman Sachs
$158→$159
Buy
55.73%
Upside
Reiterated
06/14/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Goldman Sachs
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on RYTM
Priyanka Grover
J.P. Morgan
J.P. Morgan
$146
Buy
43.00%
Upside
Reiterated
08/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Viatris (NASDAQ: VTRS)
Citizens JMP Analyst forecast on RYTM
Jonathan Wolleben
Citizens JMP
Citizens JMP
$155→$160
Buy
56.71%
Upside
Reiterated
08/05/26
Rhythm Pharmaceuticals price target raised to $160 from $155 at CitizensRhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
Canaccord Genuity Analyst forecast on RYTM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$151→$154
Buy
50.83%
Upside
Reiterated
08/05/26
Rhythm Pharmaceuticals price target raised to $154 from $151 at CanaccordRhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
Citi Analyst forecast on RYTM
Samantha Semenkow
Citi
Citi
$142→$143
Buy
40.06%
Upside
Reiterated
08/05/26
Citi Remains a Buy on Rhythm Pharmaceuticals (RYTM)
Morgan Stanley Analyst forecast on RYTM
Michael Ulz
Morgan Stanley
Morgan Stanley
$136→$150
Buy
46.91%
Upside
Assigned
08/05/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Morgan Stanley
Guggenheim Analyst forecast on RYTM
Seamus Fernandez
Guggenheim
Guggenheim
$143
Buy
40.06%
Upside
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on RYTM
Joseph Stringer
Needham
Needham
$130
Buy
27.33%
Upside
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on RYTM
Phil Nadeau
TD Cowen
TD Cowen
$130
Buy
27.33%
Upside
Assigned
08/04/26
Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Addus Homecare (NASDAQ: ADUS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Bank of America Securities Analyst forecast on RYTM
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$149
Buy
45.94%
Upside
Reiterated
08/04/26
Imcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated
RBC Capital Analyst forecast on RYTM
Lisa Walter
RBC Capital
RBC Capital
$141→$155
Buy
51.81%
Upside
Reiterated
08/04/26
Analysts' Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)
Wells Fargo Analyst forecast on RYTM
Derek Archila
Wells Fargo
Wells Fargo
$155
Buy
51.81%
Upside
Assigned
07/16/26
Wells Fargo Releases a Buy Rating on Rhythm Pharmaceuticals (RYTM)
H.C. Wainwright Analyst forecast on RYTM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$105
Buy
2.84%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals: Buy Rating Reiterated on Promising PWS Data and Large Market Opportunity; $105 Price Target Unchanged
Stifel Nicolaus Analyst forecast on RYTM
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$133
Buy
30.26%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Belite Bio, Inc. ADR (NASDAQ: BLTE)
Jefferies Analyst forecast on RYTM
Dennis Ding
Jefferies
Jefferies
$125
Buy
22.43%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies
Goldman Sachs Analyst forecast on RYTM
Corinne Johnson
Goldman Sachs
Goldman Sachs
$158→$159
Buy
55.73%
Upside
Reiterated
06/14/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Goldman Sachs
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
ACRVAcrivon Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rhythm Pharmaceuticals

3 Months
Whitney IjemCanaccord Genuity
Success Rate
20/25 ratings generated profit
80%
Average Return
+16.32%
Copying Whitney Ijem's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +16.32% per trade.
1 Year
Corinne JohnsonGoldman Sachs
Success Rate
22/22 ratings generated profit
100%
Average Return
+52.60%
Copying Corinne Johnson's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +52.60% per trade.
2 Years
Corinne JohnsonGoldman Sachs
Success Rate
22/22 ratings generated profit
100%
Average Return
+130.73%
Copying Corinne Johnson's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +130.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RYTM Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
17
18
10
8
6
Buy
19
24
19
22
20
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
42
29
30
26
In the current month, RYTM has received 26 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RYTM average Analyst price target in the past 3 months is 142.47.
Each month's total comprises the sum of three months' worth of ratings.

RYTM Financial Forecast

RYTM Earnings Forecast

Next quarter’s earnings estimate for RYTM is -$0.72 with a range of -$0.85 to -$0.57. The previous quarter’s EPS was -$0.73. RYTM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.
Next quarter’s earnings estimate for RYTM is -$0.72 with a range of -$0.85 to -$0.57. The previous quarter’s EPS was -$0.73. RYTM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.

RYTM Sales Forecast

Next quarter’s sales forecast for RYTM is $83.89M with a range of $78.00M to $93.00M. The previous quarter’s sales results were $71.25M. RYTM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.
Next quarter’s sales forecast for RYTM is $83.89M with a range of $78.00M to $93.00M. The previous quarter’s sales results were $71.25M. RYTM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.

RYTM Stock Forecast FAQ

What is RYTM’s average 12-month price target, according to analysts?
Based on analyst ratings, Rhythm Pharmaceuticals Inc’s 12-month average price target is 142.47.
    What is RYTM’s upside potential, based on the analysts’ average price target?
    Rhythm Pharmaceuticals Inc has 39.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RYTM a Buy, Sell or Hold?
          Rhythm Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Rhythm Pharmaceuticals Inc’s price target?
            The average price target for Rhythm Pharmaceuticals Inc is 142.47. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $160.00 ,the lowest forecast is $105.00. The average price target represents 39.54% Increase from the current price of $102.1.
              What do analysts say about Rhythm Pharmaceuticals Inc?
              Rhythm Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of RYTM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.